Non-viral 2A-like sequences for protein coexpression.
Medical biotechnology
Plant biotechnology
Protein expression
Recombinant antibody
Synthetic biology
Journal
Journal of biotechnology
ISSN: 1873-4863
Titre abrégé: J Biotechnol
Pays: Netherlands
ID NLM: 8411927
Informations de publication
Date de publication:
10 Nov 2022
10 Nov 2022
Historique:
received:
28
06
2022
accepted:
15
08
2022
pubmed:
23
8
2022
medline:
12
10
2022
entrez:
22
8
2022
Statut:
ppublish
Résumé
Simultaneous coexpression of multiple proteins is essential for biotechnology and synthetic biology. Currently, the most popular polyprotein coexpression system utilizes the foot-and-mouth disease virus (FMDV) 2A peptide that mediates translational ribosome-skipping events. However, due to unfavorable consumer acceptance of transgenic products containing animal-virus sequences, novel non-viral 2A-like peptides from purple sea urchin (Strongylcentrotus purpuratus) and California sea slug (Aplysia californica) were investigated for polyprotein coexpression in this study. We demonstrated that these non-viral 2A sequences functioned similarly to their viral counterpart in polyprotein processing, in both plant and mammalian cells, and were successfully used to express a functional recombinant antibody. The new non-viral 2A-like sequences offer an alternative tool for engineering multigenic traits or production of protein complexes as biomedicine via coexpression of protein subunits.
Identifiants
pubmed: 35995093
pii: S0168-1656(22)00194-8
doi: 10.1016/j.jbiotec.2022.08.014
pii:
doi:
Substances chimiques
Peptides
0
Polyproteins
0
Protein Subunits
0
Viral Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-8Informations de copyright
Copyright © 2022 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest WS and BZ are the inventors of a US patent for the intein-based polyprotein expression technology (US patent 8,945,876, issued on Feb. 3, 2015).